GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Cyclically Adjusted FCF per Share

Antibe Therapeutics (TSX:ATE) Cyclically Adjusted FCF per Share : C$-0.52 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Antibe Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was C$-0.073. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is C$-0.52 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-25), Antibe Therapeutics's current stock price is C$0.295. Antibe Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was C$-0.52. Antibe Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Antibe Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Antibe Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Cyclically Adjusted FCF per Share Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.54 -0.57

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.57 -0.57 -0.54 -0.52

Competitive Comparison of Antibe Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Antibe Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Antibe Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Antibe Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.073/125.0724*125.0724
=-0.073

Current CPI (Dec. 2023) = 125.0724.

Antibe Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.316 98.604 -0.401
201406 -0.442 99.473 -0.556
201409 -0.271 99.394 -0.341
201412 -0.280 98.367 -0.356
201503 -0.036 99.789 -0.045
201506 -0.069 100.500 -0.086
201509 -0.146 100.421 -0.182
201512 -0.134 99.947 -0.168
201603 -0.085 101.054 -0.105
201606 -0.063 102.002 -0.077
201609 -0.107 101.765 -0.132
201612 -0.077 101.449 -0.095
201703 -0.130 102.634 -0.158
201706 -0.118 103.029 -0.143
201709 -0.139 103.345 -0.168
201712 -0.052 103.345 -0.063
201803 -0.124 105.004 -0.148
201806 -0.110 105.557 -0.130
201809 -0.120 105.636 -0.142
201812 -0.066 105.399 -0.078
201903 -0.038 106.979 -0.044
201906 -0.092 107.690 -0.107
201909 -0.123 107.611 -0.143
201912 -0.090 107.769 -0.104
202003 -0.111 107.927 -0.129
202006 -0.130 108.401 -0.150
202009 -0.211 108.164 -0.244
202012 -0.176 108.559 -0.203
202103 0.454 110.298 0.515
202106 -0.104 111.720 -0.116
202109 -0.123 112.905 -0.136
202112 -0.036 113.774 -0.040
202203 -0.072 117.646 -0.077
202206 -0.088 120.806 -0.091
202209 -0.091 120.648 -0.094
202212 -0.069 120.964 -0.071
202303 -0.064 122.702 -0.065
202306 -0.087 124.203 -0.088
202309 -0.122 125.230 -0.122
202312 -0.073 125.072 -0.073

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Antibe Therapeutics  (TSX:ATE) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Antibe Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (TSX:ATE) Business Description

Industry
Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Daniel Marcel Legault Senior Officer
Alain Wilson Senior Officer
John Lawrence Wallace Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines